Your browser doesn't support javascript.
loading
Clinical and molecular characterization of patients with YWHAG-related epilepsy.
Cetica, Valentina; Pisano, Tiziana; Lesca, Gaetan; Marafi, Dana; Licchetta, Laura; Riccardi, Florence; Mei, Davide; Chung, Hon-Yin B; Bayat, Allan; Balasubramanian, Meena; Lowenstein, Daniel H; Endziniene, Milda; Alotaibi, Maha; Villeneuve, Nathalie; Jacobs, Julia; Isidor, Bertrand; Solazzi, Roberta; den Hollander, Nicolette S; Marjanovic, Dragan; Rougeot-Jung, Christelle; Jung, Julien; Lesieur-Sebellin, Marion; Accogli, Andrea; Salpietro, Vincenzo; Saadi, Nebal W; Panagiotakaki, Eleni; Foiadelli, Thomas; Redon, Sylvia; Tsai, Meng-Han; Bisulli, Francesca; Hammer, Trine B; Lupski, James R; Parrini, Elena; Guerrini, Renzo.
Afiliação
  • Cetica V; Neuroscience Department, Meyer Children's Hospital IRCCS, Florence, Italy.
  • Pisano T; Neuroscience Department, Meyer Children's Hospital IRCCS, Florence, Italy.
  • Lesca G; Université Lyon 1, Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie et Génétique du Neurone et du Muscle, Institut NeuroMyoGène, Lyon, France.
  • Marafi D; Department of Genetics, University Hospitals of Lyon, Hospices Civils de Lyon, Lyon, France.
  • Licchetta L; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
  • Riccardi F; Department of Pediatrics, Faculty of Medicine, Kuwait University, Safat, Kuwait.
  • Mei D; Istituto di Ricovero e Cura a Carattere Scientifico IRCCS, Istituto delle Scienze Neurologiche di Bologna, full member of the European Reference Network EpiCARE, Bologna, Italy.
  • Chung HB; Aix-Marseille University, Institut National de la Santé et de la Recherche Médicale (INSERM), Marseille Medical Genetics, Marseille, France.
  • Bayat A; Centre Hospitalier Intercommunal Toulon - La Seyne sur Mer (CHITS), Hôpital Ste Musse, Service de Génétique Médicale, Toulon, France.
  • Balasubramanian M; Neuroscience Department, Meyer Children's Hospital IRCCS, Florence, Italy.
  • Lowenstein DH; Department of Paediatrics and Adolescent Medicine, School of Clinical Medicine, Li Ka Shing (LKS) Faculty of Medicine, University of Hong Kong, Hong Kong, China.
  • Endziniene M; Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
  • Alotaibi M; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.
  • Villeneuve N; Department of Epilepsy Genetics and Personalized Medicine, Danish Epilepsy Center, Dianalund, Denmark.
  • Jacobs J; Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
  • Isidor B; Sheffield Clinical Genetics Service, Sheffield Children's National Health Service (NHS) Foundation Trust, Sheffield, UK.
  • Solazzi R; Department of Neurology, University of California, San Francisco, California, USA.
  • den Hollander NS; Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania.
  • Marjanovic D; King Saud Medical City, Riyadh, Saudi Arabia.
  • Rougeot-Jung C; Depatment of Pediatric Neurology, Assistance Publique-Hopitaux de Marseille (AP-HM), Hôpital de la Timone Enfants, Marseille, France.
  • Jung J; Alberta Children's Research Institute, Hodgekiss Brain Institute, Cumming School of Medicine, University of Calgary, Alberta, Canada.
  • Lesieur-Sebellin M; Service de Génétique Médicale, Centre Hospitalier Universitaire de Nantes, Nantes, France.
  • Accogli A; Université de Nantes, Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), l'Institut du Thorax, Centre Hospitalier Universitaire de Nantes, Nantes, France.
  • Salpietro V; Department of Pediatric Neuroscience, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
  • Saadi NW; Department of Clinical Genetics, Leiden University Medical Center, Leiden, the Netherlands.
  • Panagiotakaki E; Holbæk Hospital Medical Department, Holbæk, Denmark.
  • Foiadelli T; Department of Pediatric Neurology, University Hospital of Lyon, Lyon, France.
  • Redon S; Department of Functional Neurology and Epileptology, Hospices Civils de Lyon, Université de Lyon, Lyon, France.
  • Tsai MH; Department of Genomic Medicine of Rare Disorders, Necker Hospital, University Paris Cité, Paris, France.
  • Bisulli F; Division of Medical Genetics, Department of Specialized Medicine, McGill University Health Centre, Montreal, Quebec, Canada.
  • Hammer TB; Department of Human Genetics, McGill University, Montreal, Quebec, Canada.
  • Lupski JR; Department of Neuromuscular Disorders, Queen Square Institute of Neurology, University College London, London, UK.
  • Parrini E; College of Medicine, University of Baghdad, Baghdad, Iraq.
  • Guerrini R; Children Welfare Teaching Hospital, Baghdad, Iraq.
Epilepsia ; 65(5): 1439-1450, 2024 May.
Article em En | MEDLINE | ID: mdl-38491959
ABSTRACT

OBJECTIVE:

YWHAG variant alleles have been associated with a rare disease trait whose clinical synopsis includes an early onset epileptic encephalopathy with predominantly myoclonic seizures, developmental delay/intellectual disability, and facial dysmorphisms. Through description of a large cohort, which doubles the number of reported patients, we further delineate the spectrum of YWHAG-related epilepsy.

METHODS:

We included in this study 24 patients, 21 new and three previously described, with pathogenic/likely pathogenic variants in YWHAG. We extended the analysis of clinical, electroencephalographic, brain magnetic resonance imaging, and molecular genetic information to 24 previously published patients.

RESULTS:

The phenotypic spectrum of YWHAG-related disorders ranges from mild developmental delay to developmental and epileptic encephalopathy (DEE). Epilepsy onset is in the first 2 years of life. Seizure freedom can be achieved in half of the patients (13/24, 54%). Intellectual disability (23/24, 96%), behavioral disorders (18/24, 75%), neurological signs (13/24, 54%), and dysmorphisms (6/24, 25%) are common. A genotype-phenotype correlation emerged, as DEE is more represented in patients with missense variants located in the ligand-binding domain than in those with truncating or missense variants in other domains (90% vs. 19%, p < .001).

SIGNIFICANCE:

This study suggests that pathogenic YWHAG variants cause a wide range of clinical presentations with variable severity, ranging from mild developmental delay to DEE. In this allelic series, a genotype-phenotype correlation begins to emerge, potentially providing prognostic information for clinical management and genetic counseling.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Epilepsia Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Epilepsia Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article